bpc-157 cancer risk evidence as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 and the Difference Between
Description
As a human person, Im not sure
The NHS treatment page lays it out clearly: Loading phase (no neurological symptoms): 1mg every other day for two weeks, or until symptoms stop improving
Document dosing rationales (route, concentration, frequency) and use pilot results to set dose escalation or fixeddose arms in the main study
Even within the same prescription, acceptable manufacturing tolerances allow for slight variation
